RARE CANCERGenitourinaryWHO 5th Edition Classification

Penile Squamous Cell Carcinoma

Rare Malignancy (< 6 cases per 100,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

A cancer of the skin and tissues of the penis, most often squamous cell carcinoma. Around half of cases are related to human papillomavirus; the remainder are linked to chronic inflammation, phimosis, poor hygiene and smoking. It is far commoner in parts of South America, Africa and Asia than in high-income Western countries.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Any penile lesion not healing within four weeks needs biopsy, not further topical treatment
Who It Affects

Men over 60, though HPV-associated cases occur younger; childhood circumcision is protective

Annual Incidence

Under 1 per 100,000 in Europe and North America; several times higher in parts of South America, Africa and South Asia

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

A non-healing sore, ulcer or wart-like growth on the glans or foreskin
Bleeding or foul-smelling discharge
A change in skin colour or thickening of the skin
Difficulty retracting the foreskin
Lumps in the groin from lymph node spread

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

HPV 16/18 with p16 overexpression in about halfTP53CDKN2APIK3CA

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Organ-preserving surgery - glansectomy, wide local excision, laser or Mohs surgery

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Partial or total penectomy for larger or deeply invasive tumours

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Inguinal lymph node staging - dynamic sentinel node biopsy or lymphadenectomy

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Chemoradiotherapy or brachytherapy for selected organ preservation

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Cisplatin-based chemotherapy for advanced or node-positive disease

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Strongly determined by lymph node status. Node-negative disease has five-year survival above 85%, whereas pelvic nodal involvement drops this below 30%. Early accurate nodal staging is therefore the single most important management decision - delayed lymphadenectomy costs lives.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Immune checkpoint inhibitors in HPV-driven disease, and neoadjuvant chemotherapy before lymphadenectomy in bulky nodal disease, are the main trial directions; international collaboration is essential given the rarity.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Penile Squamous Cell Carcinoma

Browse All Oncologists

Dr. Philippe E. Spiess

Urologic Oncologist

15+ yrs exp

Moffitt Cancer Center

Tampa, USA

Urologic OncologyPenile CancerNodal Dissection
Vetted DirectoryConsult Specialist

Dr. Tan Teing Ee

Urologist

20+ yrs exp

SGH

Singapore, Singapore

UrologyPenile CancerPenectomy
Vetted DirectoryConsult Specialist

Prof. Henk van der Poel

Urologic Oncologist

25+ yrs exp

Netherlands Cancer Institute

Amsterdam, Netherlands

Urologic OncologyPenile Sparing TechniquesSentinel Node
Vetted DirectoryConsult Specialist

Dr. Anup Kumar

Urologic Oncologist

20+ yrs exp

Safdarjung Hospital

New Delhi, India

Urologic OncologyPenile Cancer SurgeryReconstructive Techniques
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

rare

Cancer of Unknown Primary (CUP)

rare

Malignant Mesothelioma

rare

Retinoblastoma

rare

Ewing Sarcoma

Independent Tumor Board Review

Facing a Diagnosis of Penile Squamous Cell Carcinoma?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult